At a glance
ClinicalIndex Comparison RecordPhase 2Completed· 77 enrolled
Drug / intervention
ATH-1017 +1 moredrug
Likely dose
Not stated in record
Structured eligibility isn't available for this trial yet — see the full criteria in the Eligibility tab below.
Standardized by ClinicalIndex from the ClinicalTrials.gov record · verify against the source.
A Randomized, Placebo-Controlled, Translational Study of ATH-1017 in Subjects With Mild to Moderate Alzheimer's Disease
In Brief
A Phase 2 clinical trial evaluating ATH-1017 and Placebo for Alzheimer Disease and Dementia of Alzheimer Type. Completed, enrolled 77 participants across 13 sites in 2 countries.
Detailed Summary
This study is designed to evaluate treatment effects of ATH-1017 (fosgonimeton) in mild to moderate Alzheimer's subjects with a randomized treatment duration of 26-weeks.
Study Details
Study Typeinterventional
Allocation--
Masking--
Primary Purpose--
ConditionsAlzheimer Disease, Dementia of Alzheimer Type
CountriesAustralia, United States
CollaboratorsNational Institute on Aging (NIA)
Timeline
Phase 2CompletedFinished
202120222023202420252026
First PostedJul 2020
Enrollment StartNov 2020
Primary CompletionMay 2022
TodayJul 2026
First PostedJul 29, 2020
Enrollment StartNov 23, 2020
Primary CompletionMay 20, 2022
TodayJul 2, 2026
Enrollment to primary: 1.5 yearsPosted 5.9 years ago
Interventions
ATH-1017drug
Daily subcutaneous (SC) injection of ATH-1017 in a pre-filled syringe
Placebodrug
Daily subcutaneous (SC) injection of Placebo in a pre-filled syringe